For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.